NCT06980649View on ClinicalTrials.gov

Study of BHV-1300 in Graves' Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

March 31, 2026

Conditions
Graves Disease
Interventions
DRUG

BHV-1300

BHV-1300 is delivered subcutaneously (SC)

Trial Locations (12)

2065

NOT_YET_RECRUITING

Site-006, St Leonards

2289

RECRUITING

Site-001, Kotara

3050

RECRUITING

Site-008, Parkville

3065

RECRUITING

Site-004, Fitzroy

3128

RECRUITING

Site-003, Melbourne

3228

NOT_YET_RECRUITING

Site-002, Torquay

31904

RECRUITING

Site-104, Columbus

33126

RECRUITING

Site-100, Miami

77054

RECRUITING

Site-106, Houston

77095

RECRUITING

Site-101, Houston

78231

RECRUITING

Site-105, Shavano Park

90280

RECRUITING

Site-103, South Gate

Sponsors
All Listed Sponsors
lead

Biohaven Therapeutics Ltd.

INDUSTRY